Conference abstract · 17 Jul 2017
Conference abstractPublished 17 Jul 2017
Diagnostic and prognostic markers in Non-Hodgkins Lymphoma
Minia University, Egypt; Indiana University School of Medicine, Indianapolis, Indiana
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: Establishing diagnostic and prognostic factors are very important in the management of Non-Hodgkin Lymphoma (NHL). Our aim was to evaluate the clinical significance of serum cytokines and immunological markers, in NHL patients for assessing treatment response and prognosis of patients. Methods: Serum EMAP-II, IL-19, IL-10, IL-24, TGF-Ã?², CD3, CD5, CD10, CD19, CD20, CD22, CD23, CD68, CD79a, CD99, LCA, bcl-2, bcl-6 and anticardiolipin (aCA) IgM, aCA IgG, antinulclear antibodies (ANA) levels were measured in the serum of 64 NHL patients before and after treatment with CHOP-based chemotherapy by enzyme-linked immunosorbent assay. Correlations of marker levels to the laboratory, and clinicopathological markers were performed. Results: Serum levels of EMAP-II, IL-10, CD3, CD5, CD10, CD19, CD20, CD99 and aCA IgG were higher before therapy and decreased significantly thereafter (P<0.001). Serum CD68, CD79a and bcl-6 did not change after therapy. Significantly higher levels of IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- Ã?², ANA, and aCA IgM were demonstrated in patients with relapse (P<0.001). Significant associations were found between serum markers, clinicopathological and laboratory findings. Conclusion: Cytokines and immunological markers can serve as useful diagnostic markers in NHL patients. They assessed response to therapy. Serum IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- Ã?², ANA, and aCA IgM proved to be the most sensitive predictor of advanced disease and poor prognosis.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 17 Jul 2017
Diagnostic and prognostic markers in Non-Hodgkin 's Lymphoma
Conference abstract · 13 May 2019
Efficacy of oral immunotherapy in a case of Non-Hodgkin’s Lymphoma (NHL)
Conference abstract · 13 May 2019
Efficacy of oral immunotherapy in a case of Non-Hodgkin’s Lymphoma (NHL)
Conference abstract · 17 Jul 2017
FOXO1 promotes resistance of Non-Hodgkin lymphomas to anti-CD20-based therapy
More from this journal
The newest in Immunotherapy: Open Access.
Perspective · 19 Mar 2025
Understanding the Immune Response to Checkpoint Inhibitors in Immunotherapy
Perspective · 19 Mar 2025
Advancing Immunotherapy: Future Directions in the Fight against Renal Cell Carcinoma
Short communication · 19 Mar 2025
Emerging Therapies: The Latest Developments in Autoimmune Disease Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunotherapy: Open Access
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Manal Mohamed Saber”
- BylineArticles whose byline prints “Matthias Clauss”

